Drugs /

sndx-5613

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, menin-MLL interaction inhibitor SNDX-5613 targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.

Clinical Trials

View Clinical Trials for sndx-5613

Sndx-5613 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating sndx-5613, 1 is phase 1/phase 2 (1 open).

KMT2A Fusion, NPM1 Mutation, and PML-RARA Fusion are the most frequent biomarker inclusion criteria for sndx-5613 clinical trials.

Acute leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia are the most common diseases being investigated in sndx-5613 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sndx-5613
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sndx-5613 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sndx5613, sndx 5613, menin-mll interaction inhibitor sndx-5613, menin-mll inhibitor sndx-5613, menin-mixed lineage leukemia protein-protein interaction inhibitor sndx-5613
Drug Target(s) [2]:
KMT2A
NCIT ID [1]:
C165776

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.